PHMMF (Pharma Mar) Interest Expense: $-2.5 Mil (TTM As of Mar. 2026)


PHMMF Pharma Mar SA PHMMF
82 GF Score
Price $79.49
GF Value $91.03
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Pharma Mar Interest Expense?

Pharma Mar PHMMF -25.35% 82 Interest Expense is $-2.5 Mil as of Mar. 2026. GuruFocus rates PHMMF with a GF Score™ of 82/100 and a GF Value™ of $91.03 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Pharma Mar's interest expense for the three months ended in Mar. 2026 was $ 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.5 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Pharma Mar's Operating Income for the three months ended in Mar. 2026 was $ 0.7 Mil. Pharma Mar's Interest Expense for the three months ended in Mar. 2026 was $ 0.0 Mil. GuruFocus does not calculate Pharma Mar's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pharma Mar  (OTCPK:PHMMF) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pharma Mar's Interest Expense for the three months ended in Mar. 2026 was $0.0 Mil. Its Operating Income for the three months ended in Mar. 2026 was $0.7 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $39.9 Mil.

Pharma Mar's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

GuruFocus does not calculate Pharma Mar's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Pharma Mar Interest Expense Historical Data

* Premium members only.

The historical data trend for Pharma Mar's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Mar Interest Expense Chart

Pharma Mar Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.81 -2.52 -2.64 -2.59 -2.88

Pharma Mar Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.89 -0.92 -0.14 -1.40 0.00
PHMMF
82GF Score
Pharma Mar SA PHMMF
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharma Mar Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-2.5 Mil mean?
Pharma Mar (PHMMF) has a Interest Expense of $-2.5 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Pharma Mar and its competitors.
Is Pharma Mar's Interest Expense too high?
Pharma Mar's current Interest Expense is $-2.5 Mil. Overall, Pharma Mar has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's Interest Expense compare to VRTX and REGN?
Pharma Mar's Interest Expense of $-2.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Pharma Mar and its competitors. Pharma Mar's current Interest Expense is $-2.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (PHMMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $91.03, compared to a current price of $79.49 — trading 12.7% below its estimated fair value. The current Interest Expense is $-2.5 Mil. Pharma Mar's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Pharma Mar (PHMMF), the current Interest Expense is $-2.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharma Mar (PHMMF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued. The current stock price of $79.49 is trading 12.7% below its estimated GF Value™ of $91.03. GuruFocus considers Pharma Mar to be Modestly Undervalued.

Key valuation signals for PHMMF:

  • Interest Expense: $-2.5 Mil
  • GF Value™: $91.03 vs. price of $79.49 (12.7% below fair value)
  • GF Score™: 82/100 with 3 warning signs

No single metric tells the full story. See the PHMMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharma Mar Business Description

Address Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
82GF Score

Get the complete analysis for PHMMF

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$79.49
Price
$91.03
GF Value